Artiva Biotherapeutics (ARTV) to Release Quarterly Earnings on Wednesday

Artiva Biotherapeutics (NASDAQ:ARTV) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Artiva Biotherapeutics to post earnings of ($0.64) per share for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, analysts expect Artiva Biotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Trading Up 2.0%

Shares of Artiva Biotherapeutics stock opened at $10.53 on Wednesday. Artiva Biotherapeutics has a twelve month low of $2.22 and a twelve month high of $14.53. The firm has a market capitalization of $260.30 million, a PE ratio of -2.97 and a beta of 2.18. The firm’s 50-day moving average price is $8.87 and its 200 day moving average price is $7.42.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a report on Monday, June 8th. HC Wainwright lifted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Wedbush boosted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Insider Buying and Selling

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. bought 41,319 shares of the firm’s stock in a transaction on Friday, July 24th. The shares were acquired at an average cost of $9.99 per share, with a total value of $412,776.81. Following the purchase, the director directly owned 17,283,802 shares of the company’s stock, valued at $172,665,181.98. This trade represents a 0.24% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders have bought 9,862,190 shares of company stock valued at $107,232,294 and have sold 53,040 shares valued at $477,890. Insiders own 21.40% of the company’s stock.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its position in Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares in the last quarter. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics during the third quarter worth $41,000. OMERS ADMINISTRATION Corp purchased a new stake in Artiva Biotherapeutics in the 4th quarter valued at $91,000. Bridgeway Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter valued at $53,000. Finally, Renaissance Technologies LLC increased its stake in shares of Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after acquiring an additional 37,053 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.